Therapeutic vaccines for prostate cancer: recent advances and future directions

References

• Hodi S, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. NEJM. 2010 Aug 19;363(8):711–723.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Horn L, Borghaei H, et al. Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr LBA109).
   Google Scholar
• Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372:320–330.
   PubMed Web of Science ®Google Scholar
• Spigel Dr, Reckamp KL, Rizvi NA, et al. A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC). J Clin Oncol. 2015;33(suppl; abstr 8009).
   PubMed Web of Science ®Google Scholar
• Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and Ipilimumab versus Ipilimumab in untreated melanoma. N Engl J Med. 2015;372:2006–2017.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med. 2010;363(5):411–422.
   PubMed Web of Science ®Google Scholar
• Small EJ, Schellhammer PF, Higano CS, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006;24(19):3089–3094.
   PubMed Web of Science ®Google Scholar
• Spisek R, Podrazil M, Jarolim L, et al. Cancer immunotherapy of patients with the biochemical relapse of the prostate cancer using dendritic cell-based vaccine DCVAC/PCa. J Clin Oncol. 2014;32:5s(suppl; abstr 3099).
   Google Scholar
• Suzman DL, Zhou XC, Zahurak ML, et al. Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials. Prostate Cancer Prostatic Dis. 2015 Mar;18(1):49–55. doi:10.1038/pcan.2014.44. Epub 2014 Nov 11.
   PubMed Web of Science ®Google Scholar
• Podrazil M, Horvath R, Becht E, et al. Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget. 2015;6(20):18192–18205.
   PubMed Web of Science ®Google Scholar
• DiPaola RS, Plante M, Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006;4:1. article 1
   PubMed Web of Science ®Google Scholar
• Sanda MG, Smith DC, Charles LG, et al. Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology. 1999;53(2):260–266.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Skarupa L, Pazdur M, et al. Clinical safety of a viral vector based prostate cancer vaccine strategy. J Urology. 2007 Oct;178(4 Pt 1):1515–1520. Epub 2007 Aug 16.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Wang W, Manola J, et al. Phase II randomized study of vaccine treatment of advanced prostate cancer (E7897): a trial of the Eastern cooperative oncology group. J Clin Oncol. 2004;22(11):2122–2132.
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Schuetz TJ, Blumenstein BA, et al. OS analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010;28(7):1099–1105.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Madan RA, et al. Immunologic and prognostic factors associated with OS employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother. 2010;59:663–674.
   PubMed Web of Science ®Google Scholar
• Herman JR, Adler HL, Aguilar-Cordova E, et al. In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther. 1999 May 1;10(7):1239–1249.
   PubMed Web of Science ®Google Scholar
• Miles BJ, Shalev M, Aguilar-Cordova E, et al. Prostate-specific antigen response and systemic T-cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther. 2001 Nov 1;12(16):1955–1967.
   PubMed Web of Science ®Google Scholar
• Fujita T, Teh BS, Timme TL, et al. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):84–90. Epub 2006 Feb 10.
   PubMed Web of Science ®Google Scholar
• Aguilar LK, The B, Mai W, et al. Five year follow up of a phase II study of cytotoxic immunotherapy combined with radiation in newly diagnosed prostate cancer. J Clin Oncol. 2006;24(18S): 4635. 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition), (June 20 Supplement).
   Google Scholar
• Rojas-Martínez A1, Manzanera AG, Sukin SW, et al. Intraprostatic distribution and long-term follow-up after AdV-tk immunotherapy as neoadjuvant to surgery in patients with prostate cancer. Cancer Gene Ther. 2013;20(11):642–649.
   PubMed Web of Science ®Google Scholar
• Schellhammer PF, Chodak G, Whitmore JB, et al. Lower baseline prostate-specific antigen is associated with a greater overall survival benefit from Sipuleucel-T in the immunotherapy for prostate adenocarcinoma treatment (IMPACT) trial. Urology. 2013 June;81:1297–1302.
   PubMed Web of Science ®Google Scholar
• Paller CJ, Antonarakis ES. Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions. Clin Adv Hemato Oncol H&O. 2013;11(1):14–23.
   PubMedGoogle Scholar
• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
   PubMed Web of Science ®Google Scholar
• Chi N, Tan Z, Ma K, et al. Increased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and −6 in prostate cancer. Int J Clin Exp Med. 2014;7(10):3181–3192.
   PubMed Web of Science ®Google Scholar
• Fong L, Carroll P, Weinberg V, et al. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. 2014;106(11).
   PubMed Web of Science ®Google Scholar
• Gulley JL, Heery CR, Madan RA, et al. Phase I study of intraprostatic vaccine administration in men with locally recurrent or progressive prostate cancer. Cancer Immunology, Immunotherapy: CII. 2013;62(9):1521–1531.
   PubMed Web of Science ®Google Scholar
• Farsaci B, Jochems C, Grenga I, et al. Identification by digital immunohistochemistry of intratumoral changes of immune infiltrates after vaccine in the absence of modifications of PBMC immune cell subsets. International journal of cancer. J Int Du Cancer. 2014;135(4):862–870.
   PubMed Web of Science ®Google Scholar
• Aragon-Ching JB, Williams KM, Gulley JL. Impact of androgen-deprivation therapy on the immune system: implications for combination therapy of prostate cancer. Front Biosci. 2007;12:4957–4971.
   PubMed Web of Science ®Google Scholar
• Mercader M, Bodner BK, Moser MT, et al. T-cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Natl Acad Sci USA. 2001;98:14565–14570.
   PubMed Web of Science ®Google Scholar
• Heng TS, Goldberg GL, Gray DH, et al. Effects of castration on thymocyte development in two different models of thymic involution. J Immunol. 2005;175:2982–2993.
   PubMed Web of Science ®Google Scholar
• Drake CG, Doody AD, Mihalyo MA, et al. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen. Cancer Cell. 2005;7:239–249.
   PubMed Web of Science ®Google Scholar
• Antonarakis E, Kibel A, Adams G, et al. A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): immune results. J Clin Oncol. 2013;31S:Sabstr 5016.
   Google Scholar
• Ardiani A. Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway. Oncotarget. 2014 Oct 15;5(19):9335–9348.
   PubMed Web of Science ®Google Scholar
• Ardiani A, Farsaci B, Rogers CJ, et al. Combination therapy with a second-generation androgen receptor antagonist and a metastasis vaccine improves survival in a spontaneous prostate cancer model. Clin Cancer Res. 2013 Nov 15;19(22):6205–6218.
   PubMed Web of Science ®Google Scholar
• Small EJ, Lance R, Gardner TA, et al. A randomized phase II, open-label study of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(suppl; abstr 114).
   Google Scholar
• Small EJ, Lance RS, Redfern CH, et al. A randomized phase II trial of sipuleucel-T with concurrent or sequential abiraterone acetate (AA) plus prednisone (P) in metastatic castrate-resistant prostate cancer (mCRPC). J Clin Oncol. 2013;31(suppl; abstr 5047).
   Web of Science ®Google Scholar
• Madan RA Donahue RN Singh H, et al. Clinical and immunologic impact of short course enzalutamide without androgen deprivation therapy (ADT) for biochemically recurrent prostate cancer. J Clin Oncol. 2016;34(suppl 2S; abstr 214).
   PubMed Web of Science ®Google Scholar
• Hodge JW, Garnett CT, Farsaci B, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer. 2013;133:624–636.
   PubMed Web of Science ®Google Scholar
• Ma Y, Kepp O, Ghiringhelli F, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol. 2010;22(3):113–124.
   PubMed Web of Science ®Google Scholar
• Roselli M, Cereda V, Di Bari M, et al. Effects of conventional therapeutic interventions on the number and function of regulatory T-cell. OncoImmunology. 2013;2(10):e27025.
   PubMed Web of Science ®Google Scholar
• Lutsiak ME, Semnani RT, De Pascalis R, et al. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood. 2005;105:2862–2868.
   PubMed Web of Science ®Google Scholar
• Taieb J, Chaput N, Schartz N, et al. Chemoimmunotherapy of tumors: cyclophosphamide synergizes with exosome based vaccines. J Immunol. 2006;176:2722–2729.
   PubMed Web of Science ®Google Scholar
• Arlen PM, Gulley JL, Parker C, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res. 2006;12(4):1260–1269.
   PubMed Web of Science ®Google Scholar
• Garnett CT, Palena C, Chakraborty M, et al. Sublethal irradiation of human tumor cells modulates phenotype resulting in enhanced killing by cytotoxic T lymphocytes. Cancer Res. 2004;64:7985–7994.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Coleman CN, et al. External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res. 2004;64:4328–4337.
   PubMed Web of Science ®Google Scholar
• Chakraborty M, Abrams SI, Camphausen K, et al. Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy. J Immunol. 2003;170:6338–6347.
   PubMed Web of Science ®Google Scholar
• Garnett-Benson C, Hodge JW, Gameiro SR. Combination regimens of radiation therapy and therapeutic cancer vaccines: mechanisms and opportunities. Semin Radiat Oncol. 2015;25(1):46–53.
   PubMed Web of Science ®Google Scholar
• Hiniker SM, Chen DS, Knox SJ. Abscopal effect in a patient with melanoma. N Engl J Med. 2012;366(21):2035. author reply 2035-2036.
   PubMed Web of Science ®Google Scholar
• Gulley JL, Arlen PM, Bastian A, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353–3362.
   PubMed Web of Science ®Google Scholar
• Heery CR, Madan RA, Bilusic M, et al.. A phase II randomized clinical trial of samarium-153 EDTMP (Sm-153) with or without PSA-tricom vaccine in metastatic castration-resistant prostate cancer (mCRPC) after docetaxel. J Clin Oncol. 2013;31(suppl 6; abstr 102).
   Google Scholar
• Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013;369:213–223.
   PubMed Web of Science ®Google Scholar
• O’Sullivan Coyne G, Madan RA, Gulley JL. Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol. 2014 Apr 1;32(10):986–988.
   PubMed Web of Science ®Google Scholar
• Mahoney KM, Atkins MB. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park). 2014;28(Suppl 3):39–48.
   PubMed Web of Science ®Google Scholar
• Martin AM, Nirschl TR, Nirschl CJ, et al. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance. Prostate Cancer Prostatic Disease. 2015;18:325–332;.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. N Engl J Med. 2012;366:2443–2454.
   PubMed Web of Science ®Google Scholar
• Sznol M, Chen L. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer-response. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research. 2013;19(19):5542.
   PubMed Web of Science ®Google Scholar
• Fu J, Malm IJ, Kadayakkara DK, et al. Preclinical evidence that PD1 blockade cooperates with cancer vaccine TEGVAX to elicit regression of established tumors. Cancer Res. 4042-4052;74(15):2014.
   Web of Science ®Google Scholar
• Ribas A. Tumor immunotherapy directed at PD-1. N Engl J Med. 2012;366(26):2517–2519.
   PubMed Web of Science ®Google Scholar
• Larkin J, et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015 July;2015;(373):23–34.
   Web of Science ®Google Scholar
• Madan RA, Mohebtash M, Arlen PM, et al. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet. Oncol. 2012;13(5):501–508.
   PubMed Web of Science ®Google Scholar
• Singh H, Madan RA, Dahut WL, et al. Combining active immunotherapy and immune checkpoint inhibitors in prostate cancer. J Clin Oncol. 2015;33(suppl 7; abstr 172).
   Web of Science ®Google Scholar
• Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 2014;15(7):700–712.
   PubMed Web of Science ®Google Scholar
• Van Den Eertwegh AJ, Versluis J, Van Den Berg HP, et al. Combined immunotherapy with granulocyte- macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 2012;13(5):509–517.
   PubMed Web of Science ®Google Scholar
• Wada S, Jackson CM, Yoshimura K, et al. Sequencing CTLA-4 block- ade with cell-based immunotherapy for prostate cancer. J Transl Med. 2013;11:89.
   PubMed Web of Science ®Google Scholar
• Finke JH, Rini B, Ireland J, et al. Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res. 2008 October 15;14:6674.
   PubMed Web of Science ®Google Scholar
• Ko JS, Zea AH, Rini BI, et al. Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res. 2009 Mar 15;15(6):2148–2157.
   PubMed Web of Science ®Google Scholar